U.S. Markets open in 1 hr 21 mins

Humanigen, Inc. (HGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.95+0.10 (+1.13%)
At close: 4:00PM EST

9.10 +0.15 (1.68%)
Before hours: 8:06AM EST

Humanigen, Inc.

533 Airport Boulevard
Suite 400
Burlingame, CA 94005
United States
650 243 3100

Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Dr. Cameron Durrant M.B.A., M.D., MBAChairman & CEO784.5kN/A1960
Mr. Timothy Morris CPA, CPACFO & COO66kN/A1962
Mr. David L. Tousley CPA, M.B.A., CPAChief Accounting & Admin. Officer, Corp. Sec. and TreasurerN/AN/A1956
Dr. Dale Chappell M.B.A., M.D., MBAChief Scientific OfficerN/AN/A1970
Dr. Tarek SahmoudChief Medical OfficerN/AN/AN/A
Dr. Omar Ahmed Pharm.D.Sr. VP of Clinical, Medical & Scientific AffairsN/AN/AN/A
Mr. Robert Atwill M.B.A.Head of Asia-PacificN/AN/AN/A
Mr. Edward P. Jordan M.B.A.Chief Commercial OfficerN/AN/A1968
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Corporate Governance

Humanigen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.